HUE046790T2 - A rák kezelésének módszerei - Google Patents

A rák kezelésének módszerei

Info

Publication number
HUE046790T2
HUE046790T2 HUE13786351A HUE13786351A HUE046790T2 HU E046790 T2 HUE046790 T2 HU E046790T2 HU E13786351 A HUE13786351 A HU E13786351A HU E13786351 A HUE13786351 A HU E13786351A HU E046790 T2 HUE046790 T2 HU E046790T2
Authority
HU
Hungary
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
HUE13786351A
Other languages
English (en)
Inventor
Sarah Knutson
Natalie Warholic
Heike Keilhack
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of HUE046790T2 publication Critical patent/HUE046790T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
HUE13786351A 2012-10-15 2013-10-15 A rák kezelésének módszerei HUE046790T2 (hu)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261714145P 2012-10-15 2012-10-15
US201261714045P 2012-10-15 2012-10-15
US201261714140P 2012-10-15 2012-10-15
US201361758972P 2013-01-31 2013-01-31
US201361780703P 2013-03-13 2013-03-13
US201361786277P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
HUE046790T2 true HUE046790T2 (hu) 2020-03-30

Family

ID=49519104

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13786351A HUE046790T2 (hu) 2012-10-15 2013-10-15 A rák kezelésének módszerei

Country Status (23)

Country Link
US (6) US9688665B2 (hu)
EP (2) EP2908823B1 (hu)
JP (5) JP6351182B2 (hu)
KR (3) KR20230156450A (hu)
CN (2) CN105142642B (hu)
AU (4) AU2013331368A1 (hu)
BR (1) BR112015008447A2 (hu)
CA (2) CA3177498A1 (hu)
CY (1) CY1122186T1 (hu)
ES (1) ES2750199T3 (hu)
HK (1) HK1213771A1 (hu)
HR (1) HRP20191814T1 (hu)
HU (1) HUE046790T2 (hu)
IL (4) IL288181B2 (hu)
LT (1) LT2908823T (hu)
MX (2) MX2015004771A (hu)
NZ (2) NZ706836A (hu)
PL (1) PL2908823T3 (hu)
PT (1) PT2908823T (hu)
RS (1) RS59541B1 (hu)
RU (2) RU2677276C2 (hu)
SI (1) SI2908823T1 (hu)
WO (1) WO2014062720A2 (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
RS55690B1 (sr) 2012-04-13 2017-07-31 Epizyme Inc So inhibitora ljudske histonske metiltransferaze ezh2
AU2013331380B2 (en) * 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MA38949A1 (fr) 2013-10-16 2017-07-31 Eisai R&D Man Co Ltd Forme saline d'hydrochlorure pour inhibition d'ezh2
US20160228447A1 (en) * 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
EA201691079A1 (ru) 2013-12-06 2017-03-31 Эпизим, Инк. Комбинированная терапия для лечения онкологического заболевания
LT3157527T (lt) * 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
JP6684230B2 (ja) 2014-06-19 2020-04-22 メモリアル スローン ケタリング キャンサー センター Ｅｚｈ２阻害剤への応答についてのバイオマーカー
NZ730365A (en) 2014-10-16 2024-03-22 Epizyme Inc Method for treating cancer
FI3220916T3 (fi) * 2014-11-17 2023-06-19 Epizyme Inc Menetelmä syövän hoitoon n-((4,6-dimetyli-2-okso-1,2-dihydropyridin-3-yyli)metyyli)-5-(etyyli(tetrahydro-2h-pyran-4-yyli)amino)- 4-metyyli-4'-(morfolinometyyli)-[1,1'-bifenyyli]-3-karboksamidilla
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
SG11201708286PA (en) * 2015-04-20 2017-11-29 Epizyme Inc Combination therapy for treating cancer
CN107635965A (zh) * 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2017053930A2 (en) * 2015-09-25 2017-03-30 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
CN108699046A (zh) * 2015-10-06 2018-10-23 Epizyme股份有限公司 用ezh2抑制剂治疗成神经管细胞瘤的方法
EP3370725A4 (en) * 2015-11-06 2019-07-03 Epizyme, Inc. PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
CN105440023A (zh) * 2015-12-10 2016-03-30 江苏理工学院 Epz-6438的合成方法
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
JP2019508406A (ja) * 2016-02-08 2019-03-28 エピザイム，インコーポレイティド 癌を処置する方法
WO2017201585A1 (en) * 2016-05-26 2017-11-30 Genea Ip Holdings Pty Ltd Modulators of dux4 for regulation of muscle function
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
CN109312407A (zh) * 2016-06-08 2019-02-05 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
US20190192521A1 (en) * 2016-08-15 2019-06-27 The Wistar Institute Of Anatomy And Biology Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors
WO2018049000A1 (en) * 2016-09-08 2018-03-15 The General Hospital Corporation Treatment of cancers having alterations within the swi/snf chromatin remodeling complex
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
CN110366413A (zh) * 2017-02-02 2019-10-22 Epizyme股份有限公司 癌症治疗形式
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
AU2018369841A1 (en) 2017-11-14 2020-05-07 Pfizer Inc. EZH2 inhibitor combination therapies
AU2019214861B2 (en) 2018-01-31 2021-11-18 Mirati Therapeutics, Inc. PRC2 inhibitors
EP3823671B1 (en) * 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
TWI798532B (zh) * 2019-03-25 2023-04-11 大陸商深圳微芯生物科技股份有限公司 Ｋｄｍ５ａ基因和ａｔｒｘ基因的應用
WO2020198717A1 (en) * 2019-03-27 2020-10-01 The Johns Hopkins University Methods and materials for assessing and treating cancer
WO2020219606A1 (en) 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
KR20220027216A (ko) 2019-06-28 2022-03-07 에이엘에스 테라피 디벨럽먼트 인스티튜트 디펩타이드 반복 단백질의 억제
WO2021173960A1 (en) * 2020-02-28 2021-09-02 The Wistar Institute Of Anatomy And Biology Treatment of carm1-overexpressing and/or arid1a mutant cancers with ire-1/xbp-1 inhibitors
AU2021293943A1 (en) * 2020-06-18 2023-02-23 Epizyme, Inc. SMARCA4 inhibition for the treatment of cancer
CN111773387A (zh) * 2020-07-08 2020-10-16 北京大学 一种通过改变bin1剪切体比例改善心脏横管结构的方法
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
CN116019916A (zh) * 2021-10-27 2023-04-28 蚌埠医学院第一附属医院 非小细胞肺癌靶点arid1a及其抑制剂在制备肺癌治疗药物中的用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20110064664A1 (en) * 2007-10-08 2011-03-17 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
NZ603454A (en) 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
WO2012071096A2 (en) * 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
ES2570380T3 (es) 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
US20130310379A1 (en) * 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (ja) * 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
US20140296248A1 (en) * 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
AU2012315566A1 (en) * 2011-09-30 2014-04-17 Glaxosmithkline Llc Methods of treating cancer
WO2013059944A1 (en) 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof
AU2013232229B2 (en) 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9932317B2 (en) * 2012-03-19 2018-04-03 Imperial Innovations Limited Quinazoline compounds and their use in therapy
NZ700759A (en) * 2012-04-13 2017-03-31 Epizyme Inc Combination therapy for treating cancer
RS55690B1 (sr) * 2012-04-13 2017-07-31 Epizyme Inc So inhibitora ljudske histonske metiltransferaze ezh2
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors

Also Published As

Publication number Publication date
AU2023282217A1 (en) 2024-01-04
IL308613A (en) 2024-01-01
IL273517A (en) 2020-05-31
WO2014062720A3 (en) 2014-06-19
HK1213771A1 (zh) 2016-07-15
MX2020010535A (es) 2020-11-06
IL238254B (en) 2020-04-30
KR20190105669A (ko) 2019-09-17
IL288181B2 (en) 2024-04-01
AU2018233004A1 (en) 2018-10-11
US20190100514A1 (en) 2019-04-04
US20170305890A1 (en) 2017-10-26
LT2908823T (lt) 2019-10-25
US20220315566A1 (en) 2022-10-06
US9688665B2 (en) 2017-06-27
US20140128393A1 (en) 2014-05-08
AU2020205261B2 (en) 2023-09-14
JP2015536308A (ja) 2015-12-21
JP2018062535A (ja) 2018-04-19
US20200262823A1 (en) 2020-08-20
RS59541B1 (sr) 2019-12-31
IL288181B1 (en) 2023-12-01
CN105142642B (zh) 2019-10-18
KR20230156450A (ko) 2023-11-14
JP6351182B2 (ja) 2018-07-04
EP2908823B1 (en) 2019-09-25
CA3177498A1 (en) 2014-04-24
HRP20191814T1 (hr) 2019-12-27
PL2908823T3 (pl) 2020-03-31
BR112015008447A2 (pt) 2017-07-04
US20170305889A1 (en) 2017-10-26
ES2750199T3 (es) 2020-03-25
RU2677276C2 (ru) 2019-01-16
EP3659606A1 (en) 2020-06-03
JP2020011971A (ja) 2020-01-23
IL238254A0 (en) 2015-06-30
NZ746054A (en) 2020-07-31
AU2018233004B2 (en) 2020-04-16
CN105142642A (zh) 2015-12-09
JP2024029066A (ja) 2024-03-05
KR20150086264A (ko) 2015-07-27
RU2018145311A (ru) 2019-02-18
RU2015118144A (ru) 2016-12-10
WO2014062720A2 (en) 2014-04-24
AU2013331368A1 (en) 2015-04-30
SI2908823T1 (sl) 2019-11-29
JP2021120420A (ja) 2021-08-19
PT2908823T (pt) 2019-11-04
CA2887243A1 (en) 2014-04-24
KR102021642B1 (ko) 2019-09-16
NZ706836A (en) 2019-02-22
EP2908823A2 (en) 2015-08-26
CA2887243C (en) 2024-04-09
IL288181A (en) 2022-01-01
AU2020205261A1 (en) 2020-08-06
CY1122186T1 (el) 2020-11-25
CN110898067A (zh) 2020-03-24
MX2015004771A (es) 2016-01-08

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL237791B (en) A method for treating cancer
SG11201503893RA (en) Method of treating cancer
EP2760452A4 (en) METHODS OF TREATING CANCER
HK1202240A1 (en) Methods of treating cancer
HK1214128A1 (zh) 癌症的治療
HK1213817A1 (zh) 治療癌症的方法
HK1205254A1 (en) Methods of treatment of cancer
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
GB201217892D0 (en) Treatment of cancer
HK1219513A1 (zh) 治療癌症的方法
HK1204956A1 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201208296D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer